The study sponsored by Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia aims to elucidate the immune modulation effects of adjuvant radiotherapy in patients with high-risk cSCC. Given the increasing incidence of skin cancers and the potential for improved patient outcomes through enhanced understanding of immune responses, this research could inform future therapeutic strategies and positioning in the oncology market. The findings may also provide insights into patient stratification for immunotherapy approaches, potentially enhancing the competitive landscape against existing treatments. The study's outcomes could be pivotal for companies developing immunomodulatory therapies or combination treatments involving radiotherapy.